Top Markets
#1 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +18.57%
#2 Movement Movement +6.40%
#3 Palladium Network Palladium Network +5.02%
#4 Prom Prom +4.17%
#5 GRVT Token GRVT Token +3.87%
#6 Cryptopia Cryptopia +3.74%
#7 SIXSEVEN SIXSEVEN +3.67%
#8 Test Test +3.60%
#9 Kinetiq Kinetiq +3.58%
#10 Jito Jito +3.53%
Coin of the day
FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock)
Tetapan
Bahasa
MALAY
Mata wang
USD
Tema
FluoroPharma Medical, Inc. FluoroPharma Medical, Inc.

FluoroPharma Medical, Inc.

FPMI
Kedudukan dalam Saham #41957
FluoroPharma Medical, Inc. (FPMI) is a biopharmaceutical firm dedicated to the... FluoroPharma Medical, Inc. (FPMI) is a biopharmaceutical firm dedicated to the discovery, development, and commercialization of advanced molecular imaging agents. Initially, its efforts are concentrated on cardiovascular applications within the United States market. The company's pipeline features two notable product candidates: BFPET: An imaging agent designed for stress-testing patients with suspected or confirmed coronary artery disease (CAD), which has successfully completed its Phase I clinical trial. CardioPET: Another molecular imaging agent, currently undergoing a Phase IIa clinical trial. This compound aims to evaluate myocardial blood flow and metabolism in individuals afflicted with CAD. FluoroPharma Medical has established key collaborations, including licensing agreements with Massachusetts General Hospital and Sinotau USA. Furthermore, the company holds clinical research agreements with Pharmaceutical Product Development, LLC, and Cardiovascular Imaging Technologies. Established in 2003, FluoroPharma Medical, Inc. is headquartered in Montclair, New Jersey.
Harga Saham
$0.0002
Disegerakkan terakhir: 2026-08-11
Modal Pasaran
$6.85K
Perubahan (1 hari)
0.00%
Perubahan (1 tahun)
100.00%
Negara
US
Perdagangan FluoroPharma Medical, Inc. (FPMI)

Kategori

Healthcare
Pendapatan untuk FluoroPharma Medical, Inc. (FPMI)
Pendapatan pada 2026 TTM: 0
Menurut laporan kewangan terkini FluoroPharma Medical, Inc., pendapatan semasa syarikat ialah 0. Pada tahun 2026, syarikat memperoleh pendapatan sebanyak 0, sama dengan pendapatan pada tahun 2026 yang berjumlah 0. Pendapatan yang dipaparkan di halaman ini adalah pendapatan sebelum faedah dan cukai atau dikenali sebagai EBIT.
Sejarah pendapatan bagi FluoroPharma Medical, Inc. dari 2026 hingga 2026
Pendapatan pada akhir setiap tahun
Tahun Pendapatan Ubah
Tidak cukup data untuk tarikh yang disediakan.
Pendapatan untuk syarikat atau pesaing serupa
Syarikat Pendapatan Perbezaan Pendapatan Negara
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
$3.01B -
BE
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
- -
KR